Consequences of verteporfin photodynamic therapy on choroidal neovascular membranes

Archives of Ophthalmology

Volumn 124, Issue 6, 2006, Pages 815-823

  Tatar, Olcay ^a   Kaiserling, Edwin ^b   Adam, Annemarie ^b   Gelisken, Faik ^a   Shinoda, Kei ^c   Völker, Michael ^a   Lafaut, Bart A ^d   Bartz Schmidt, Karl Ulrich ^a   Grisanti, Salvatore ^a,b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c National Hospital Organization   (Japan)

^d AZ StJan ^*  (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CYTOKERATIN 18; ENDOGLIN; KI 67 ANTIGEN; VASCULOTROPIN;

ANGIOGENESIS; CELL PROLIFERATION; ENDOTHELIUM CELL; HUMAN; IMMUNOREACTIVITY; PHOTODYNAMIC THERAPY; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SUBRETINAL NEOVASCULARIZATION;

AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, CD34; CELL PROLIFERATION; CHOROID; CHOROIDAL NEOVASCULARIZATION; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KERATINS; KI-67 ANTIGEN; MALE; MEMBRANES; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; RECEPTORS, CELL SURFACE; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33745013336     PISSN: 00039950     EISSN: 00039950     Source Type: Journal    
DOI: 10.1001/archopht.124.6.815     Document Type: Review

References (34)

1. Ghafour IM, Allan D, Foulds WS. Common causes of blindness and visual handicap in the west of Scotland. Br J Ophthalmol. 1983;67:209-213.
2. Hyman L. Epidemiology of eye disease in the elderly. Eye. 1987;1:330-341.
3. Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol. 2000;45:195-214.
4. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials: TAP report 1. Arch Ophthalmol. 1999;117:1329-1345.
5. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials: TAP report 2. Arch Ophthalmol. 2001;119:198-207.
6. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes: TAP report No. 3. Arch Ophthalmol. 2002;120:1443-1454.
7. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization: verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2001;131:541-560.
8. Blinder KJ, Bradley S, Bressler NM, et al; Treatment of Age-related Macular Degeneration With Photodynamic Therapy Study Group; Verteporfin in Photodynamic Therapy Study Group. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report No. 1. Am J Ophthalmol. 2003;136:407-418.
9. Grossniklaus HE, Ling JX, Wallace TM, et al. Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis. 2002;8:119-126.
10. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 1996;37:1929-1934.
11. Amin R, Pulkin JE, Frank RN. Growth factor localization in choroidal neovascular membranes of age-related macular degeneration. Invest Ophthalmol Vis Sci. 1994;35:3178-3188.
12. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1996;37:855-868.
13. Wada M, Ogata N, Otsuji T, Uyama M. Expression of vascular endothelial growth factor and its receptor (KDR/fek-1) mRNA in experimental choroidal neovascularization. Curr Eye Res. 1999;18:203-213.
14. Kwak N, Okamoto N, Wood J, Campochiaro P. VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2000;41:3158-3164.
15. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol. 2002;120:338-346.
16. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 1996;380:435-439.
17. Blaauwgeers HG, Holtkamp GM, Rutten H, et al. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris: evidence for a trophic paracrine relation. Am J Pathol. 1999;155:421-428.
18. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A. 1995;92:10457-10461.
19. Smith LE, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994;35:101-111.
20. Grisanti S, Tatar O, Canbek S, et al. Immunohistopathologic evaluation of choroidal neovascular membranes following verteporfin photodynamic therapy. Am J Ophthalmol. 2004;137:914-923.
21. Michels S, Schmidt-Erfurth U. Sequence of early vascular events after photodynamic therapy. Invest Ophthalmol Vis Sci. 2003;44:2147-2154.
22. Schmidt-Erfurth U, Laqua H, Schlötzer-Schrehardt U, Vistenz A, Naumann GOH. Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol. 2002;120:835-844.
23. Schlötzer-Schrehardt U, Vistenz A, Naumann GOH, Laqua H, Michels S, Schmidt-Erfurth U. Dose-dependent structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol. 2002;240:748-757.
24. Shima DT, Adamis AP, Ferrara N, et al. Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol Med. 1995;1:182-193.
25. Kuroki M, Voest EE, Amano S, et al. Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest. 1996;98:1667-1675.
26. Schmidt-Erfurth UM, Michels S. Changes in confocal indocyanine green angiography through two years following photodynamic therapy with verteporfin Ophthalmology. 2003;110:1306-1314.
27. Schmidt-Erfurth U, Michels S, Barbazetto I, Laqua H. Photodynamic effects on choroidal neovascularization and physiological choroids. Invest Ophthalmol Vis Sci. 2002;43:830-841.
28. Schlingemann RO. Role of growth factors and the wound healing response in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2004;242:91-101.
29. Spilsbury K, Garrett KL, Shen WY, Constable IJ, Rakoczy PE. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol. 2000;157:135-144.
30. Bula DV, Iliaki E, Gragoudas E, Miller JW, Arroyo J. Pigment epithelium-derived factor, angiopoietin-1, and VEGF expression in human choroidal neovascular membranes treated with photodynamic therapy [ARVO abstract]. Invest Ophthalmol Vis Sci. 2004;45:E-abstract 1787. http://www.iovs.org. Accessed February 15, 2005.
31. Schmidt-Erfurth U, Schlötzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GOH. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci. 2003;44:4473-4480.
32. Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina. 2002;22:143-152.
33. Eyetech Study Group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology. 2003;110:979-986.
34. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805-2816.